ots Ad hoc-Service: curasan AG <DE0005494538> curasan turnover increases by 48% as at 30 September
13.11.2000 – 07:26
Kleinostheim (ots Ad hoc-Service) -
Ad hoc-announcement edited and sent by DGAP. The sender is solely responsible for the contents of this announcement.
curasan AG, Kleinostheim,(WKN 549453) is continuing its high-level growth. The turnover for the specialist in regenerative biomedicne increased by nearly 48% to DM 15.9 million (compared with 10.8 million last year) in the first nine months of 2000. Last year's turnover was exceeded this year in just the third quarter. The export share was 13%, nearly double that of the previous year. After evaluating the provisional figures, the Executive Board announced that the EBIT, including proportional depreciations in company value, should have improved in the same period.
Biologicals and Biomaterials showed a growth trend by achieving about 40% of the total turnover (compared with 31% the previous year). One of the most significant growth vehicles is the synthetic bone regeneration material Cerasorb, which has been vigorously marketed internationally. The marketing of Cerasorb as a block material and in fittings, has begun along with the present granulates, and this should also promote turnover. An international patent application has been made for the solid forms. The Pharmaceuticals sector - in particular local anaesthetics, antibiotics, anaesthetics and a fibrinolytic drug - decreased to around 60% of earnings (compared with 69% last year) because of the strong growth of the other two areas.
The Executive Board believes that the company will continue to grow and that a high-level turnover growth will be achieved at the end of the business year.
The complete quarterly report will be published on 20 November.
curasan AG Executive Board
Original content of: Curasan AG, transmitted by news aktuell